ArticleFrontiers in cardiovascular medicine2026
Observational study on initiation of dapagliflozin in heart failure with reduced ejection fraction in the United Kingdom.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sodium-glucose cotransporter-2 inhibitor (SGLT2i) dapagliflozin has shown favourable outcomes in trials for heart failure with reduced ejection fraction (HFrEF), but little is known about real-world prescribing practices, tolerability, or impact on patient quality of life (QoL) in the United Kingdom. Methods: This study was an observational longitudinal cohort study of adult patients with HFrEF in the UK, following the date of first initiation of dapagliflozin. Baseline patient characteristics, concomitant medication prescribed at enrolment, and changes to these treatments were recorded at 3, 6, 9 and 12 months following initiation. Patients completed KCCQ-23, MARS-5 and WPAI patient-reported outcome measures to assess QoL, treatment adherence and work/activity impairment, respectively, at enrolment and follow-up. Results: N = 237 patients were enrolled, with Conclusions: Patients receiving dapagliflozin recorded low levels of discontinuation, suggesting high tolerability. Many patients do not receive all four recommended treatment pillars, highlighting an opportunity for further treatment optimization. Patients had fair-to-good QoL throughout the study, indicating good patient experience during HFrEF treatment including dapagliflozin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.